Stifel raised the firm’s price target on Erasca (ERAS) to $30 from $20 and keeps a Buy rating on the shares after having hosted a “confidence-inspiring” dinner with the Erasca CEO Jonathan Lim and CFO/CBO David Chacko in San Diego. The firm’s sense and investor feedback was that management sounded very confident heading into ERAS-0015 data from the U.S. and Chinese dose escalation studies, the analyst stated.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERAS:
- Erasca Tightens Timeline for ERAS-0015 Phase 1 Data
- ERAS: Promising RAS-Mutant Oncology Pipeline and China Partnership Support Buy Rating
- Bar remains unchanged for Erasca after Revolution’s ‘clear win,’ says Jefferies
- Erasca drops 9% to $15.54 after Revolution pancreatic cancer data
- Erasca falls -7.9%